Skip to main content
. 2020 Mar 12;6(5):1–5. doi: 10.1001/jamaoncol.2020.0007

Figure 1. CONSORT Flow Diagram.

Figure 1.

Between December 2014 and June 2016, 1204 patients were screened for eligibility, 961 patients were randomized at 57 sites, 945 started treatment (intention-to-treat population), and 938 underwent surgery.1 Of these 938 patients, 24 patients were not included in this secondary analysis because no DNA sample was available. BC indicates breast cancer; CONSORT, Consolidated Standards of Reporting Trials; HR, hormone receptor; iddEPC, intense dose-dense epirubicin, paclitaxel, and cyclophosphamide; PM(Cb), paclitaxel and nonpegylated liposomal doxorubicin with or without carboplatin; TNBC, triple-negative BC.